Acute leukemia is one of the most common malignant tumors in children, occupying the first place in childhood cancer mortality. Of these, acute myeloid leukemia (AML) accounts for 20% to 30%. At present, the clinical treatment of AML still mainly relies on combination of chemotherapy and hematopoietic stem cell transplantation (HSCT), but the adverse reactions of chemotherapy are extremely grave. Therefore, exploring new ways to treat leukemia has become an urgent task for the effective treatment of leukemia.
Iron is one of the basic nutrients required for cell viability. Deferoxamine (DFO) is a widely used iron chelator in the clinic, and it is often used in the treatment of siderosis. In recent years, it has been reported that DFO can inhibit tumor cell proliferation and induce apoptosis (
1-
4), suggesting that DFO may be used as an anti-tumor agent. Indeed, DFO can inhibit the proliferation of prostate cancer, breast cancer, neuroblastoma, and leukemia cells (
5,
6). Callens et al. proved that iron metabolism was an effective target for the treatment of AML (
7). According to a study, DFO significantly enhanced the activity of dexamethasone, doxorubicin, and L-asparaginase, thus mitigating the multidrug resistance of leukemia (
8). DFO also induced an increase in intracellular calcium, enhancing the sensitivity to doxorubicin as a chemotherapeutic drug (
9).
Mitochondrial autophagy has become a research hotspot in recent years. Lemasters found that the decrease in mitochondrial membrane potential and the opening of mitochondrial permeability membrane pores could cause mitochondrial autophagy, and he proposed the concept of mitochondrial autophagy (
10). Studies have shown that Parkin and Pink1 proteins are involved in the execution of mitochondrial autophagy induced by a decrease in membrane potential (
11,
12). Therefore, the specific mechanism of mitochondrial autophagy can be elucidated by detecting the expression of these proteins.